My 2 Favorite Stocks to Buy Right Now
These two stocks will be at the top of my shortlist of stocks to add to in October.
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Zoetis ( ZTS ) Surpasses Market Returns: Some Facts Worth Knowing
Zoetis (ZTS) concluded the recent trading session at $143.5, signifying a +1.68% move from its prior day's close.
Why Is Phibro ( PAHC ) Down 1.1% Since Last Earnings Report?
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phibro Animal Health Stock Surges 82.1% YTD: What's Fueling It?
PAHC rallies 82% YTD with booming vaccines, MFAs and global expansion fueling investor confidence.
How Do Investors Really Feel About Zoetis? - Zoetis ( NYSE:ZTS )
Zoetis's ZTS short interest as a percent of float has risen 17.45% since its last report. According to exchange reported data, there are now 7.76 million shares sold short, which is 1.75% of all regular shares that are available for trading.
Zoetis ( ZTS ) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Zoetis (ZTS) stood at $146.25, denoting a -1.32% move from the preceding trading day.
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
Should You Invest in the VanEck Agribusiness ETF ( MOO ) ?
Sector ETF report for MOO ...
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR ( SDZNY Quick QuoteSDZNY - ) or Zoetis ( ZTS Quick QuoteZTS - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find ...
Here's Why You Should Add PAHC Stock to Your Portfolio Right Now
Phibro Animal Health posts strong Animal Health sales growth, aided by a Zoetis acquisition, while Mineral Nutrition and Performance Products rebound.
Zoetis ( ZTS ) Stock Sinks As Market Gains: Here's Why
Zoetis (ZTS) reached $149.79 at the closing of the latest trading day, reflecting a -1.29% change compared to its last close.
If You Invested $1000 in Zoetis a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
PAHC Stock Surges on Q4 Earnings & Revenue Beat, Gross Margin Down
Phibro Animal Health posts strong Q4 earnings and revenues, fueled by Animal Health growth. Meanwhile, the gross margin contracts.
Phibro Animal Health Stock Surges 18% After-Hours On Strong Q4 Earnings Beat - Phibro Animal Health ( NASDAQ:PAHC )
Phibro Animal Health Corporation PAHC shares jumped 17.98% to $37.99 in after-hours trading on Thursday, following strong fourth-quarter results that beat expectations. Check out the current price of PAHC stock here. The global animal health company reported fourth-quarter net sales of $378.7 ...
Phibro Animal Health Q4 Revenue Up 39%
Phibro Animal Health ( NASDAQ:PAHC ) , a veterinary pharmaceutical and nutrition provider, reported earnings for Q4 FY2025 on August 27, 2025, covering the three months ending June 30. Driven by its largest-ever acquisition and strong international appetite for its medicated feed additives, the ...
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
PAHC Stock Up 76.4% in a Year: What's Driving the Rally?
Phibro Animal Health's 76.4% stock surge is fueled by strong sales recovery, global growth and a robust balance sheet.
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners.
If You'd Invested $1,000 in Zoetis ( ZTS ) Stock 10 Years Ago, Here's How Much You'd Have Today
The short-term picture has been less rosy than the longer-term one.
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR ( SDZNY Quick QuoteSDZNY - ) and Zoetis ( ZTS Quick QuoteZTS - ) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
Veterinary Diagnostics Market is expected to generate a revenue of USD 4.52 Billion by 2031, Globally, at 6.59% CAGR: Verified Market Research®
Lewes, Delaware, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- The Global Veterinary Diagnostics Market Size is projected to grow at a CAGR of 6.59% from 2024 to 2031, according to a new report published by Verified Market Research®.
2 Stocks to Buy With $5,000 and Hold for a Decade
These two stocks come from completely different industries, but each could boost a long-term investor's returns.
Why Zoetis ( ZTS ) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
What's Going On With Zoetis Stock Tuesday? - Zoetis ( NYSE:ZTS )
Zoetis Q2 EPS rose to $1.76 vs. $1.61 estimate; revenue hit $2.50 billion, beating $2.41 billion forecast. Full-year EPS guidance raised to $6.30-$6.40 from $6.20-$6.30. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. Animal health firm Zoetis Inc.
Zoetis ( ZTS ) Q2 Earnings and Revenues Surpass Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of +8.64% and +2.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
1 Top Dividend Growth Stock to Buy and Hold Forever
The demand for this company's products will continue increasing.
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
BioCryst Pharmaceuticals ( BCRX ) Surpasses Q2 Earnings and Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of +400.00% and +9.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Market Whales and Their Recent Bets on ZTS Options - Zoetis ( NYSE:ZTS )
Investors with a lot of money to spend have taken a bearish stance on Zoetis ZTS. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
Countdown to Zoetis ( ZTS ) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Here's Why Zoetis ( ZTS ) Fell More Than Broader Market
In the latest trading session, Zoetis (ZTS) closed at $148.81, marking a -1.46% move from the previous day.
Aclaris Therapeutics ( ACRS ) Expected to Beat Earnings Estimates: Should You Buy?
Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Trump's pharmaceutical tariffs could affect some drugmakers more than others
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
Zoetis ( ZTS ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Do Investors Really Feel About Zoetis? - Zoetis ( NYSE:ZTS )
Zoetis's ZTS short percent of float has fallen 14.56% since its last report. The company recently reported that it has 7.85 million shares sold short, which is 1.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.87 days to cover their ...
Billionaire Terry Smith Sold Fundsmith's Entire Stake in Apple and 11X'd His Position in a Company Whose Addressable Market Can Hit $149 Billion by 2032
The "Warren Buffett of Britain" dumped Buffett's actual No. 1 holding in favor a stock with the legs to run higher.
USNA or ZTS: Which Is the Better Value Stock Right Now?
USNA vs. ZTS: Which Stock Is the Better Value Option?
Zoetis ( ZTS ) Laps the Stock Market: Here's Why
In the most recent trading session, Zoetis (ZTS) closed at $151.19, indicating a +2.59% shift from the previous trading day.
Why Zoetis ( ZTS ) Could Beat Earnings Estimates Again
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here's Why Zoetis ( ZTS ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Invest in the VanEck Agribusiness ETF ( MOO ) ?
Sector ETF report for MOO ...
Phibro ( PAHC ) Soars 6.8%: Is Further Upside Left in the Stock?
Phibro (PAHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost - Phibro Animal Health ( NASDAQ:PAHC )
JPMorgan upgrades Phibro Animal Health citing strong FY2025 performance and upside potential. Analyst expects healthy FY2026 growth in MFAs, vaccines and nutritional specialties. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
SGIOY vs. ZTS: Which Stock Is the Better Value Option?
3 Magnificent S&P 500 Dividend Stocks Down 19% to 26%: Is It Time to Buy the Dip?
I am an adherent to the Gardner-Kretzmann Continuum's strategy of owning at least one stock for each year of your age. Because of this notion, I have 37 "core" holdings that I try to add to consistently over time.However, while the S&P 500 has returned to new highs, three of my core holdings -- a ...
2 Dividend Growth Stocks to Buy and Hold Forever
For investors focused on the long game, there is little reason to sell -- at least, so long as a company generates solid returns through consistently improving financial results, regularly increases its dividend ( if it pays one ) , and maintains strong growth prospects.
